Edition:
United States

Cancer Genetics Inc (CGIX.OQ)

CGIX.OQ on NASDAQ Stock Exchange Capital Market

0.93USD
18 May 2018
Change (% chg)

$0.03 (+2.76%)
Prev Close
$0.90
Open
$0.93
Day's High
$0.93
Day's Low
$0.90
Volume
5,927
Avg. Vol
95,458
52-wk High
$4.32
52-wk Low
$0.83

Chart for

About

Cancer Genetics, Inc. is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide... (more)

Overall

Beta: 1.30
Market Cap(Mil.): $25.34
Shares Outstanding(Mil.): 27.75
Dividend: --
Yield (%): --

Financials

  CGIX.OQ Industry Sector
P/E (TTM): -- 28.03 32.53
EPS (TTM): -0.35 -- --
ROI: -17.74 7.52 12.63
ROE: -21.66 10.73 14.50

BRIEF-Cancer Genetics Reports Q1 Loss Per Share $0.16

* CANCER GENETICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES STRATEGIC BUSINESS UPDATES

May 15 2018

BRIEF-Cancer Genetics Says Appointed John Roberts As CEO And President

* CANCER GENETICS SAYS ON APRIL 30, BOARD APPOINTED JOHN ROBERTS AS COMPANY'S CEO AND PRESIDENT - SEC FILING Source: (https://bit.ly/2w2ruOW) Further company coverage:

May 01 2018

BRIEF-Cancer Genetics Reports Q4 Loss Per Share Of $0.35

* CANCER GENETICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES STRATEGIC BUSINESS UPDATES

Apr 02 2018

BRIEF-Cancer Genetics Receives Non-Dilutive Funding Of $1.1 Mln

* CANCER GENETICS RECEIVES NON-DILUTIVE FUNDING OF $1.1 MILLION THROUGH NEW JERSEY TECHNOLOGY BUSINESS TAX CERTIFICATE TRANSFER (NOL) PROGRAM

Dec 28 2017

BRIEF-Stonepine Capital Management Reports 5 Percent Passive Stake In Cancer Genetics

* STONEPINE CAPITAL MANAGEMENT REPORTS 5 PERCENT PASSIVE STAKE IN CANCER GENETICS INC AS ON DEC 12 - SEC FILING Source: (http://bit.ly/2p5v6Mx) Further company coverage:

Dec 21 2017

BRIEF-Cancer Genetics Prices $7 Million Registered Direct Offering

* CANCER GENETICS PRICES $7 MILLION REGISTERED DIRECT OFFERING

Dec 08 2017

Competitors

Earnings vs. Estimates